



US009370483B2

(12) **United States Patent**  
**Dhuppad et al.**

(10) **Patent No.:** **US 9,370,483 B2**  
(45) **Date of Patent:** **\*Jun. 21, 2016**

(54) **STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE**

(71) Applicant: **Glenmark Pharmaceuticals Limited,**  
Mumbai (IN)

(72) Inventors: **Ulhas R. Dhuppad,** Maharashtra (IN);  
**Ashok Katkurwar,** Maharashtra (IN);  
**Yashwant Gupta,** Maharashtra (IN);  
**Rajesh Ankam,** Maharashtra (IN);  
**Chandrakant Dhatrak,** Maharashtra (IN)

(73) Assignee: **GLENMARK SPECIALTY S.A.,** La  
Chaux-de-Fonds (CH)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/662,128**

(22) Filed: **Mar. 18, 2015**

(65) **Prior Publication Data**

US 2015/0250718 A1 Sep. 10, 2015

#### **Related U.S. Application Data**

(63) Continuation-in-part of application No. 14/483,837, filed on Sep. 11, 2014, now Pat. No. 9,078,923, which is a continuation-in-part of application No. PCT/IB2014/064251, filed on Sep. 4, 2014.

(30) **Foreign Application Priority Data**

Sep. 13, 2013 (IN) ..... 2975/MUM/2013

(51) **Int. Cl.**

**A61K 31/00** (2006.01)  
**A61K 31/335** (2006.01)  
**A61K 31/58** (2006.01)  
**A61K 47/36** (2006.01)  
**A61K 47/38** (2006.01)  
**A61K 9/10** (2006.01)  
**A61K 9/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 9/0043** (2013.01); **A61K 9/10** (2013.01); **A61K 31/00** (2013.01); **A61K 31/335** (2013.01); **A61K 31/58** (2013.01); **A61K 47/36** (2013.01); **A61K 47/38** (2013.01)

(58) **Field of Classification Search**

CPC . **A61K 2300/00**; **A61K 31/58**; **A61K 9/0043**; **A61K 31/335**; **A61K 31/57**; **A61K 31/573**; **A61K 31/355**; **A61K 31/5513**; **A61K 31/56**; **A61K 31/575**; **A61K 31/7048**; **A61K 9/0073**; **A61K 9/10**; **A61K 9/145**; **A61K 9/01**

See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

4,871,865 A	10/1989	Lever, Jr. et al.
4,923,892 A	5/1990	Lever, Jr. et al.
5,837,699 A	11/1998	Sequeira et al.
6,127,353 A	10/2000	Yuen et al.
7,977,376 B2	7/2011	Singh et al.
8,399,508 B2	3/2013	Singh et al.
9,078,923 B2 *	7/2015	Dhuppad ..... A61K 9/0043
2004/0097474 A1	5/2004	Cagle et al.
2006/0110328 A1	5/2006	Cagle et al.
2008/0058296 A1	3/2008	Chaudry
2012/0121653 A1	5/2012	Jenkins et al.
2015/0099725 A1	4/2015	Khairatkar-Joshi et al.
2015/0272966 A1	10/2015	Khairatkar-Joshi et al.

#### **FOREIGN PATENT DOCUMENTS**

WO	WO-9520393	8/1995
WO	WO-0126658	4/2001
WO	WO-2006057769 A2	6/2006
WO	WO-2009003199	12/2008
WO	WO-2010025236 A1	3/2010
WO	WO-2011008923 A2	1/2011
WO	WO-2011141929 A2	11/2011
WO	WO-2012094283	7/2012
WO	WO-2014092346 A1	6/2014

#### **OTHER PUBLICATIONS**

Austin, et al., Mometasone Furoate is a Less Specific Glucocorticoid than Fluticasone Propionate, Eur Respir J, 2002, 20:1386-1392.  
Avicel® RC-591, Product Specification Bulletin, Feb. 2009.  
Baja, et al., Benefits of Skin Prick Tests for Allergic Rhinitis, The Internet Journal of Otorhinolaryngology, 2006, 6:1.  
International Search Report for International Application PCT/IB2014/064251 dated Nov. 19, 2014, pp. 1-13.  
Johnson, M., Ph.D., Development of Fluticasone Propionate and Comparison with Other Inhaled Corticosteroids, J Allergy Clin Immunol, Apr. 1998, 101:4:P2:S434-S439.  
Nsouli, et al., Combination of a Nasal Antihistamine Olopatadine and a Nasal Corticosteroid, Mometasone . . . , International Scientific Conference, Dubai, UAE, Dec. 2010.  
Roland, et al., Olopatadine Nasal Spray for the Treatment of Seasonal Allergic Rhinitis in Patients Aged 6 years and older, Expert Opin Pharmacother, 2010, 11:9:1559-1567.

(Continued)

*Primary Examiner* — Audrea Buckley

(74) *Attorney, Agent, or Firm* — Blank Rome LLP

(57) **ABSTRACT**

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

**21 Claims, No Drawings**